▲ bullish
Impact
PhasePhase 2 completed; preparing for Phase 3 (SPECTRUM program)
Time to marketIf the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.
NDV-01 Updated Nov 15
What to watch
The next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.
Bull case
- Phase 2 data showed a 76% durable complete response rate at 12 months in NMIBC, with 86% of 12-month complete responders maintaining response at 18 months, suggesting a durable treatment effect.
- Relmada has a strong cash position of $202.1M (Q3 2026), expected to fund operations through 2029, removing near-term financing risk.
- CEO Sergio Traversa and CFO Maged Shenouda collectively purchased ~$1.67M of stock in open-market transactions in September 2026, a strong insider conviction signal.
Bear case
- Relmada has no approved products or revenue; it is entirely dependent on NDV-01 clinical trial success after its prior lead drug REL-1017 failed Phase 3 in depression (2022/2024), causing an 80% stock drop in December 2024.
- The Phase 2 data showed two BCG-naive patients progressed to muscle-invasive disease at Month 15, a potential safety signal that could complicate FDA review.
- The company has massively diluted shareholders: shares outstanding grew from ~30M at end-2024 to ~105M by May 2026, and an S-3 shelf registration filed in May 2026 signals potential further dilution.